RCP Therapeutics has appointed Prof Volkmar Weissig to its Scientific Advisory Board (SAB) to strengthen its expertise in sub-cellular targeting and mitochondrial medicine.
Volkmar Weissig is associate professor of pharmacology at the department of pharmaceutical sciences, Midwestern University College of Pharmacy, Glendale, Arizona.
He previously served as assistant professor of pharmaceutics at Northeastern University, Boston.
In particular, the presence of Prof Weissig enhances RCP's scientific expertise in the field of nano-carrier assisted sub-cellular targeting and mitochondrial nanomedicine.
'Prof Weissig is recognised as one of the pre-eminent scientists in the realm of sub-cellular targeting and mitochondrial nanomedicine,' said Robert Sexauer, chief executive officer of RCP Therapeutics.
'He was recently interviewed by MIT Technology Review to discuss our licensed technology that was demonstrated to be more effective in treating cancers than existing alternatives.
'This is due to the fact that reformulated anti-cancer chemotherapy with mitochondrial sub-cellular targeting ligand is able to bypass or evade cancer multi-drug resistance mechanisms and instruct cancer cells to commit suicide.' RCP plans to further develop its technologies, take products through clinical trials and ultimately bring them to market in the hope of delivering a real breakthrough in cancer drug treatment.
Prof Weissig will be part of this critical process.
